

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1548)**

## **SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING**

**REFERENCES ARE MADE TO** the circular (the “**Circular**”) of Genscript Biotech Corporation (the “**Company**”) and the notice of the annual general meeting (the “**Meeting**”) of the Company (the “**Notice**”) both dated 25 April 2022, of which set out the time and venue of the Meeting and the resolutions to be put forward to the shareholders of the Company (“**Shareholders**”) for approval. This supplemental notice should be read together with the Notice.

**SUPPLEMENTAL NOTICE IS HEREBY GIVEN** that the Meeting will be held at Conference Room, No. 1129 Shenfeng Road, Shangfang Town, Jiangning District, Nanjing, Jiangsu Province, PRC at 9:30 a.m. on Friday, 27 May 2022 for the following purpose:

5. To re-elect Dr. Zhang Fangliang as non-executive Director.

By Order of the Board  
**Genscript Biotech Corporation**  
**Meng Jiange**  
*Chairman*

Hong Kong, 11 May 2022

*Registered office:*  
4th Floor, Harbour Place  
103 South Church Street  
George Town, P.O. Box 10240  
Grand Cayman KY1-1002  
Cayman Islands

*Principal place of business in Hong Kong:*  
40th Floor, Dah Sing Financial Centre  
No. 248 Queen’s Road East  
Hong Kong

*Notes:*

- (i) A second proxy form (the “**Second Proxy Form**”) containing the additional ordinary resolution numbered 5 is enclosed with the supplemental circular to the Shareholders dated 11 May 2022 (the “**Supplemental Circular**”). Please refer to the section headed “SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING AND SECOND PROXY FORM” on pages 4 to 5 of the Supplemental Circular for arrangements on the completion and submission of the Second Proxy Form.
- (ii) Save for the above supplemental resolution, there are no other changes to the resolutions set out in the Notice. Please refer to the Notice for details of the other ordinary resolutions to be considered at the Meeting, closure of register of members of the Company and the eligibility for attending the Meeting, proxy and other relevant matters.
- (iii) Whether or not the Shareholders are able to attend the Meeting in person, the Shareholders are required to complete the Second Proxy Form in accordance with the instructions printed thereon and return it to the Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong.
- (iv) The Shareholders are reminded that return of the First Proxy Form and/or the Second Proxy Form will not preclude the Shareholders from attending and voting in person at the Meeting or any adjournment thereof should they so wish.
- (v) All dates and times mentioned in this supplemental notice refer to Hong Kong dates and times.
- (vi) As at the date of this notice, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Zhang Fangliang, Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Juan and Dr. Wang Xuehai.